NECVAXNEO1(NECVAXNEO1) - 在研适应症：三阴性乳腺癌，实体瘤，黑色素瘤_专利_临床

概要

基本信息

药物类型

DNA疫苗、治疗性疫苗

别名

NECVAXNEO1、Personalised neoantigen-targeting cancer vaccine( NEC Corp)、NECVAX NEO1

靶点-

作用机制

免疫刺激剂

治疗领域

肿瘤皮肤和肌肉骨骼疾病口颌疾病+ [2]

在研适应症

三阴性乳腺癌实体瘤黑色素瘤+ [4]

非在研适应症-

原研机构

在研机构

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

5

项与 NECVAXNEO1 相关的临床试验

NCT06631092 / Recruiting临床1/2期

An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 as add-on to First-line Neoadjuvant Anti-PD-1 Monoclonal Antibody Therapy in Patients With Triple-negative Breast Cancer

Phase I/II, multicenter, open-label, single-arm trial in triple-negative breast cancer patients under first-line neoadjuvant therapy with approved standard of care anti-PD-1 monoclonal antibody (PD-1 inhibitor), epirubicin/cyclophosphamide chemotherapy, and nab-paclitaxel therapy. NECVAX-NEO1 treatment in addition to standard of care anti-PD1 monoclonal antibody therapy can be prolonged after breast cancer surgery for another 24 weeks, according to the investigator's decision taking into consideration the study patient's health status.

开始日期2024-12-15

申办/合作机构

NEC Corp.

[+1]

NCT06631079 / Recruiting临床1/2期

An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Patients With Solid Tumors

Phase I/II multicenter, open-label, single-arm trial in patients to evaluate the safety and effect of NECVAX-NEO1 administered in combination with PD-1/PD-L1 mABs in patients with solid tumors. Patients with solid tumors who will be treated with approved standard of care (SoC) PD-1 or PD-L1 monoclonal antibody inhibitor therapy, and who after starting treatment with PD-1/PD-L1 inhibitor reached either Stable Disease (SD) or Partial Response (PR) (Cohort 1) or PD (Cohort 2) according to RECIST 1.1 and iRECIST assessed at the Baseline visit may be enrolled in the study

开始日期2024-10-07

申办/合作机构

NEC Corp.

[+1]

CTIS2024-513716-95-00 / Recruiting

- NECVAX-NEO1-LT

开始日期2022-05-16

申办/合作机构

NEC OncoImmunity AS

100 项与 NECVAXNEO1 相关的临床结果

登录后查看更多信息

100 项与 NECVAXNEO1 相关的转化医学

登录后查看更多信息

100 项与 NECVAXNEO1 相关的专利（医药）

登录后查看更多信息

100 项与 NECVAXNEO1 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
三阴性乳腺癌	临床2期	德国	NEC Corp.	2024-12-15
实体瘤	临床2期	西班牙	NEC Corp.	2024-10-07
黑色素瘤	临床1期	立陶宛	NEC OncoImmunity AS	2022-05-05
口腔肿瘤	临床1期	立陶宛	NEC OncoImmunity AS	2022-05-05
非小细胞肺癌	临床1期	立陶宛	NEC OncoImmunity AS	2022-05-05
肾细胞癌	临床1期	立陶宛	NEC OncoImmunity AS	2022-05-05
头颈部鳞状细胞癌	临床1期	立陶宛	NEC OncoImmunity AS	2022-05-05